Description (from grant):
A consortium of five studies was established to examine potential risk and protective factors that influence vulnerability to AD, including: gender, genetics, cognitive reserve, physical activity, personality, depression and vascular risk factors. The extensive longitudinal clinical and cognitive data, and rich biomarker collection from the consortium sites offer a unique opportunity to address these important issues.
The Preclinical AD Consortium was established in 2014 to accelerate understanding of the preclinical phase of AD. While each of these studies has federal funding to support the longitudinal collection of clinical, cognitive, genetic and biomarker data among individuals who were cognitively normal when first enrolled, it is understood that it is essential to combine their data together in order to address some of the most challenging questions related to the evolution of AD during its earliest phases. One of the primary goals of these studies has been to identify individuals at greatest risk for progression in order to facilitate early intervention. However, these studies have also been gathering information relevant to risk and protective factors that may influence vulnerability to disease. These factors are challenging to study because the effect of any one risk factor may be modest and large sample sizes are needed in order to examine potential interactions of effects, particularly as they pertain to biomarkers of disease. This application provides the unique opportunity to leverage the data prospectively collected by five ongoing studies of preclinical AD to examine a range of risk and protective factors that may influence risk for progression from normal cognition to mild cognitive impairment. We are also proposing additional biomarker assays (in blood and cerebrospinal fluid) and the generation of new genetic data, to address selected issues. The potential risk and protective factors the consortium is proposing to examine include: gender, genetics, cognitive reserve, physical activity, personality, depression and vascular risk factors. The consortium represented by this application, with its' extensive longitudinal clinical and cognitive data, and rich biomarker collection (including blood, CSF, MRI scans and PET scans) offers a unique opportunity to address these important issues.
Sur S, Lin Z, Li Y, Yasar S, Rosenberg P, Moghekar A, Hou X, Kalyani R, Hazel K, Pottanat G, Xu C, van Zijl P, Pillai J, Liu P, Albert M, Lu H. Association of cerebrovascular reactivity and Alzheimer pathologic markers with cognitive performance. Neurology 2020 Jul 13:10.1212/WNL.0000000000010133. Online ahead of print.
Jiang D, Lin Z, Liu P, Sur S, Xu C, Hazel K, Pottanat G, Darrow J, Pillai JJ, Yasar S, Rosenberg P, Moghekar A, Albert M, Lu H. Brain Oxygen Extraction Is Differentially Altered by Alzheimer's and Vascular Diseases. J Magn Reson Imaging. 2020 Jun 21. Online ahead of print
Tward D, Brown T, Kageyama Y, Patel J, Hou Z, Mori S, Albert M, Troncoso J, Miller M. Diffeomorphic Registration With Intensity Transformation and Missing Data: Application to 3D Digital Pathology of Alzheimer's Disease. Front Neurosci. 2020 Feb 11;14:52.
Hua J, Lee S, Blair NIS, Wyss M, van Bergen JMG, Schreiner SJ, Kagerer SM, Leh SE, Gietl AF, Treyer V, Buck A, Nitsch RM, Pruessmann KP, Lu H, Van Zijl PCM, Albert M, Hock C, Unschuld PG. Increased cerebral blood volume in small arterial vessels is a correlate of amyloid-β-related cognitive decline. Neurobiol Aging. 2019 Apr;76:181-193.